Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Neoplasms 5Stomach Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Advanced Solid Tumors 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Thoracic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

Gemcitabine 7Cystectomy 5Cisplatin 5durvalumab 4Neoadjuvant Therapy 4Mitomycin 4Transurethral Resection of Bladder 3Nivolumab 3Epirubicin 3Chemoradiotherapy 3BCG Vaccine 3Anesthesia, Spinal 3tislelizumab 2disitamab vedotin 2catumaxomab 2atezolizumab 2Vitamin E 2Urinary Diversion 2Sunitinib 2Selenium 2Robotic Surgical Procedures 2Multiparametric Magnetic Resonance Imaging 2Magnetic Resonance Imaging 2Immunohistochemistry 2Fentanyl 2Docetaxel 2Diathermy 2Cystoscopy 2Chemoprevention 2BCG Connaught 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Urinary Bladder Neoplasms × Injections × Clear all
NCT05488353 2022-08-04

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 4 Unknown
48 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡